Remove Chemotherapy Remove Immunization Remove Labelling
article thumbnail

Immunocore claims first-ever FDA approval for TCR cancer therapy

pharmaphorum

“Every year in the US, hundreds of people are diagnosed with metastatic uveal melanoma who, until now, had no approved treatment options,” said Immunocore chief executive Bahija Jallal.

FDA 124
article thumbnail

EC approves Regeneron’s immunotherapy for cervical cancer

Pharmaceutical Technology

Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. Based on the open-label, multicentre, international Phase III EMPOWER-Cervical 1 clinical trial findings, the regulatory agency granted approval in advanced cervical cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US FDA grants approval for AstraZeneca’s lung cancer therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

FDA 52
article thumbnail

Who should not take probiotics?

The Checkup by Singlecare

A healthy gut biome is crucial to your immune system and regulates proper digestion, bowel movements, and other bodily functions. People with compromised immune systems. Anyone with food allergies should thoroughly review the label, research the company, and consult their allergist or healthcare provider before taking probiotics.

article thumbnail

Prednisone (predniSONE Intensol) for cats

The Checkup by Singlecare

It suppresses the immune system response at high doses and can treat problems such as rheumatoid arthritis. Autoimmune conditions Autoimmune disorders (or inflammatory disorders) are diseases caused by the immune system. Typically, the immune system targets foreign organisms and other substances.

Dosage 98
article thumbnail

EC approves Regeneron’s Libtayo for advanced cervical cancer

pharmaphorum

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The results were published in the New England Journal of Medicine.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections. What do you envision the future of radiopharmaceuticals to be like?